The University of Chicago Header Logo

Mark Kozloff

Concepts (291)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Combined Chemotherapy Protocols
46
2022
2550
2.570
Why?
Colorectal Neoplasms
14
2022
980
1.720
Why?
Angiogenesis Inhibitors
8
2014
315
1.240
Why?
Antibodies, Monoclonal
11
2017
1399
1.020
Why?
Antibodies, Monoclonal, Humanized
21
2021
967
0.920
Why?
Bevacizumab
19
2022
287
0.840
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
3
2021
157
0.790
Why?
Disease-Free Survival
22
2022
1213
0.730
Why?
Lung Neoplasms
12
2014
2344
0.720
Why?
Carcinoma, Non-Small-Cell Lung
8
2014
1113
0.660
Why?
Fluorouracil
24
2022
561
0.620
Why?
Carcinoma, Squamous Cell
7
2022
1095
0.540
Why?
Leucovorin
15
2022
224
0.520
Why?
Neoplasm Metastasis
15
2017
1107
0.520
Why?
Indazoles
2
2012
67
0.520
Why?
Aged
53
2019
19019
0.510
Why?
Imidazoles
2
2012
148
0.500
Why?
Middle Aged
61
2022
25787
0.490
Why?
Pancreatic Neoplasms
7
2019
666
0.480
Why?
Maximum Tolerated Dose
10
2019
272
0.480
Why?
Paclitaxel
8
2019
478
0.460
Why?
TNF-Related Apoptosis-Inducing Ligand
1
2013
25
0.460
Why?
Carcinoma, Large Cell
2
2011
39
0.450
Why?
Head and Neck Neoplasms
12
2022
1062
0.440
Why?
Registries
2
2016
773
0.430
Why?
Aged, 80 and over
25
2019
6758
0.400
Why?
Survival Rate
15
2019
1881
0.390
Why?
Vascular Endothelial Growth Factor A
4
2014
420
0.390
Why?
Treatment Outcome
21
2019
8178
0.380
Why?
Indoles
7
2014
312
0.370
Why?
Pyrroles
6
2014
187
0.370
Why?
Adult
45
2019
26439
0.350
Why?
Female
59
2022
45899
0.340
Why?
Male
53
2022
42135
0.340
Why?
Liver Neoplasms
3
2019
754
0.330
Why?
Deoxycytidine
7
2019
238
0.330
Why?
Carcinoma, Lobular
1
2009
81
0.330
Why?
Carcinoma, Ductal, Breast
1
2009
158
0.310
Why?
Gastrointestinal Neoplasms
2
2019
111
0.310
Why?
Adenocarcinoma
7
2011
1194
0.310
Why?
Glucuronosyltransferase
2
2019
186
0.300
Why?
Salvage Therapy
2
2019
235
0.300
Why?
Humans
70
2022
88852
0.290
Why?
Colonic Neoplasms
4
2022
573
0.290
Why?
ErbB Receptors
7
2014
500
0.290
Why?
Bone Neoplasms
1
2009
328
0.290
Why?
Antineoplastic Agents
10
2022
2410
0.280
Why?
Organoplatinum Compounds
7
2017
97
0.270
Why?
Disease Progression
10
2018
1483
0.260
Why?
Camptothecin
5
2022
193
0.260
Why?
Quinazolines
4
2012
221
0.260
Why?
Prognosis
11
2019
3757
0.250
Why?
Carboplatin
5
2012
304
0.230
Why?
Breast Neoplasms
7
2014
2991
0.230
Why?
Cohort Studies
7
2014
2855
0.230
Why?
Neoplasm Recurrence, Local
7
2018
1354
0.220
Why?
Quinolines
2
2019
91
0.190
Why?
Rectal Neoplasms
1
2022
127
0.190
Why?
Neoplasm Staging
12
2015
1989
0.190
Why?
Pyrazoles
2
2019
150
0.190
Why?
Intestinal Perforation
2
2012
35
0.190
Why?
Prospective Studies
7
2022
4258
0.180
Why?
Cisplatin
11
2012
617
0.180
Why?
Lymphoma, Non-Hodgkin
2
2018
261
0.170
Why?
Thromboembolism
2
2010
120
0.170
Why?
Receptors, Transforming Growth Factor beta
1
2019
45
0.160
Why?
Sulfonamides
4
2021
317
0.160
Why?
Protein Kinase Inhibitors
3
2012
602
0.150
Why?
Androstenes
1
2018
45
0.150
Why?
Food
1
2018
89
0.150
Why?
Pyridines
2
2019
315
0.150
Why?
Survival Analysis
6
2019
1533
0.140
Why?
Molecular Targeted Therapy
1
2019
285
0.140
Why?
Epithelial-Mesenchymal Transition
1
2017
96
0.140
Why?
Carcinoma, Pancreatic Ductal
1
2017
112
0.140
Why?
Prostatic Neoplasms, Castration-Resistant
1
2018
121
0.140
Why?
Dose-Response Relationship, Drug
6
2019
1938
0.140
Why?
Young Adult
5
2016
6271
0.130
Why?
Polymorphism, Genetic
1
2019
824
0.130
Why?
Proportional Hazards Models
4
2014
848
0.130
Why?
Anilides
1
2015
48
0.130
Why?
Chromosome Aberrations
1
2016
390
0.130
Why?
Hedgehog Proteins
1
2015
100
0.120
Why?
Kaplan-Meier Estimate
5
2017
858
0.120
Why?
Drug Administration Schedule
6
2019
894
0.120
Why?
Biomarkers, Tumor
6
2019
1532
0.120
Why?
Disease Management
1
2016
328
0.120
Why?
Methotrexate
6
1992
250
0.120
Why?
Hypertension
2
2010
741
0.120
Why?
MicroRNAs
1
2019
550
0.120
Why?
Receptors, TNF-Related Apoptosis-Inducing Ligand
1
2013
3
0.120
Why?
Follow-Up Studies
5
2019
3649
0.120
Why?
Neoplasms
4
2014
3020
0.110
Why?
Exanthema
1
2014
39
0.110
Why?
Blood Proteins
1
2014
145
0.110
Why?
Pilot Projects
4
2017
865
0.110
Why?
Proteomics
1
2014
230
0.100
Why?
Adenocarcinoma, Bronchiolo-Alveolar
1
2011
20
0.100
Why?
Practice Patterns, Physicians'
1
2016
598
0.100
Why?
Adolescent
10
2014
9201
0.100
Why?
Time Factors
6
2014
5313
0.090
Why?
Clinical Trials, Phase III as Topic
1
2011
172
0.090
Why?
Combined Modality Therapy
7
2008
1708
0.090
Why?
Bendamustine Hydrochloride
2
2021
11
0.090
Why?
Alkaline Phosphatase
1
2010
132
0.090
Why?
Statistics as Topic
1
2011
234
0.090
Why?
Diabetes Complications
2
2010
170
0.090
Why?
Randomized Controlled Trials as Topic
3
2012
832
0.090
Why?
Arthritis, Rheumatoid
1
1991
169
0.090
Why?
Lymphoma
1
1991
264
0.090
Why?
Rituximab
2
2021
119
0.090
Why?
Bridged Bicyclo Compounds, Heterocyclic
2
2021
88
0.090
Why?
Tissue Distribution
1
2009
292
0.080
Why?
Safety
1
2010
149
0.080
Why?
Everolimus
2
2022
40
0.080
Why?
Signal Transduction
2
2018
3370
0.080
Why?
Double-Blind Method
3
2019
1713
0.080
Why?
Lymphatic Metastasis
2
2009
502
0.080
Why?
Proto-Oncogene Proteins c-met
1
2009
200
0.080
Why?
Skin Diseases
1
2009
173
0.080
Why?
Prostatic Neoplasms
2
2011
1767
0.070
Why?
Hemorrhage
1
2009
278
0.070
Why?
Carcinoma
1
2010
442
0.070
Why?
Precision Medicine
1
2011
408
0.070
Why?
Neoplasms, Hormone-Dependent
1
2006
41
0.070
Why?
Taxoids
3
2012
130
0.070
Why?
Multivariate Analysis
4
2014
986
0.070
Why?
Prostate-Specific Antigen
3
2018
358
0.070
Why?
Erlotinib Hydrochloride
3
2011
90
0.070
Why?
Dacarbazine
1
2006
102
0.060
Why?
Product Surveillance, Postmarketing
1
2004
38
0.060
Why?
Prednisone
2
2018
258
0.060
Why?
Amifostine
1
2004
51
0.060
Why?
Drug Eruptions
1
2004
34
0.060
Why?
Radiation-Protective Agents
1
2004
98
0.060
Why?
Thionucleotides
1
2004
56
0.060
Why?
Carcinoma, Small Cell
1
2004
133
0.060
Why?
Capecitabine
2
2014
98
0.050
Why?
Sex Factors
2
2019
1062
0.050
Why?
Proto-Oncogene Proteins c-bcl-2
1
2004
196
0.050
Why?
Drug Resistance, Neoplasm
2
2018
615
0.050
Why?
Age Factors
2
2019
1862
0.050
Why?
Remission Induction
6
2008
738
0.050
Why?
Genotype
2
2019
1848
0.040
Why?
Brain Neoplasms
1
2006
780
0.040
Why?
Etoposide
3
2008
198
0.040
Why?
Longitudinal Studies
2
2013
1066
0.040
Why?
Stomach Neoplasms
2
2019
281
0.040
Why?
Albumins
1
2019
129
0.040
Why?
Azetidines
1
2019
37
0.040
Why?
Chemotherapy-Induced Febrile Neutropenia
1
2018
6
0.040
Why?
Biliary Tract Neoplasms
1
2019
33
0.040
Why?
Phenylurea Compounds
1
2019
114
0.040
Why?
United States
4
2018
6931
0.040
Why?
Epithelial Cells
1
2022
688
0.040
Why?
Singapore
1
2018
16
0.040
Why?
Radiotherapy, Conformal
1
1999
84
0.040
Why?
Placebos
1
2018
214
0.040
Why?
Dehydroepiandrosterone
1
2018
49
0.040
Why?
Piperidines
1
2019
164
0.040
Why?
Filgrastim
1
2017
57
0.040
Why?
Fasting
1
2018
163
0.040
Why?
Peripheral Nervous System Diseases
1
1998
87
0.040
Why?
Patient Safety
1
2019
215
0.040
Why?
Transforming Growth Factor beta
1
2018
321
0.030
Why?
Testosterone
1
2018
275
0.030
Why?
Postoperative Care
1
2017
228
0.030
Why?
Neoplasms, Squamous Cell
1
1996
20
0.030
Why?
Academic Medical Centers
1
2019
384
0.030
Why?
Technetium
1
1995
29
0.030
Why?
Radioimmunodetection
1
1995
13
0.030
Why?
Karnofsky Performance Status
1
2015
40
0.030
Why?
Chemotherapy, Adjuvant
1
2017
485
0.030
Why?
Glucocorticoids
1
2018
356
0.030
Why?
Drug Therapy, Combination
5
2011
780
0.030
Why?
Polyethylene Glycols
1
2017
358
0.030
Why?
Preoperative Care
1
2017
395
0.030
Why?
Interferon-alpha
4
1998
226
0.030
Why?
Immunoglobulin Fab Fragments
1
1995
82
0.030
Why?
Lymphoma, B-Cell
1
1995
105
0.030
Why?
Neuropilin-2
1
2014
2
0.030
Why?
Neuropilin-1
1
2014
14
0.030
Why?
Pemetrexed
1
2014
76
0.030
Why?
Trastuzumab
1
2014
71
0.030
Why?
Glutamates
1
2014
89
0.030
Why?
Recombinant Proteins
4
1998
1011
0.030
Why?
Odds Ratio
1
2015
684
0.030
Why?
Cetuximab
1
2014
117
0.030
Why?
Caspase 3
1
2013
161
0.030
Why?
Anemia, Sideroblastic
1
1993
7
0.030
Why?
Inflammation
1
2019
969
0.030
Why?
Guanine
1
2014
207
0.030
Why?
Sirolimus
1
2014
170
0.030
Why?
Antimetabolites, Antineoplastic
1
2014
237
0.030
Why?
Zinc
1
1993
93
0.030
Why?
Risk Factors
2
2014
5448
0.030
Why?
Fatigue
1
2013
178
0.030
Why?
Peritoneal Neoplasms
2
2005
184
0.020
Why?
Regression Analysis
2
2009
590
0.020
Why?
Chromosomal Instability
1
2011
19
0.020
Why?
Ploidies
1
2011
41
0.020
Why?
Risk Assessment
1
2019
2286
0.020
Why?
Loss of Heterozygosity
1
2011
86
0.020
Why?
Neoplastic Cells, Circulating
1
2011
71
0.020
Why?
ras Proteins
1
2011
130
0.020
Why?
Proto-Oncogene Proteins p21(ras)
1
2011
164
0.020
Why?
Semaphorins
1
2009
17
0.020
Why?
Depression
1
2013
502
0.020
Why?
Chicago
1
2014
1423
0.020
Why?
Transforming Growth Factor alpha
1
2009
50
0.020
Why?
Predictive Value of Tests
1
2014
1713
0.020
Why?
Demography
1
2009
181
0.020
Why?
Immunosuppressive Agents
1
2014
975
0.020
Why?
Vascular Endothelial Growth Factor Receptor-2
1
2009
84
0.020
Why?
Mutation
2
2011
4121
0.020
Why?
Substance-Related Disorders
1
1993
414
0.020
Why?
Gene Amplification
1
2008
134
0.020
Why?
RNA, Messenger
1
2014
2011
0.020
Why?
DNA Mutational Analysis
1
2009
529
0.020
Why?
Feasibility Studies
1
2010
778
0.020
Why?
Exons
1
2009
451
0.020
Why?
In Situ Hybridization, Fluorescence
1
2008
354
0.020
Why?
Piperazines
1
2009
283
0.020
Why?
Radiotherapy Dosage
2
1999
470
0.020
Why?
Polymerase Chain Reaction
1
2009
921
0.020
Why?
Proto-Oncogene Proteins
1
2011
666
0.020
Why?
Biomarkers
1
2014
1753
0.020
Why?
Neoadjuvant Therapy
1
2010
366
0.020
Why?
Hydroxyurea
2
1998
239
0.020
Why?
Ketoconazole
1
2006
26
0.020
Why?
Enzyme Inhibitors
1
2009
645
0.020
Why?
Receptors, Estrogen
3
1983
386
0.020
Why?
Bleomycin
2
1990
102
0.020
Why?
Mitoxantrone
1
2006
68
0.020
Why?
Models, Molecular
1
2009
1294
0.020
Why?
Vincristine
2
1983
112
0.020
Why?
Erythema Multiforme
1
2004
4
0.020
Why?
Retrospective Studies
1
2019
8963
0.020
Why?
Blister
1
2004
8
0.020
Why?
Quality of Life
1
2013
1661
0.020
Why?
Stevens-Johnson Syndrome
1
2004
22
0.020
Why?
Radiometry
1
2004
56
0.010
Why?
Oligonucleotides, Antisense
1
2004
68
0.010
Why?
Stereoisomerism
2
1996
102
0.010
Why?
Severity of Illness Index
1
2008
1835
0.010
Why?
Algorithms
1
2010
1870
0.010
Why?
Mice
1
2015
11722
0.010
Why?
Melphalan
1
1981
98
0.010
Why?
Clinical Trials as Topic
2
2004
1146
0.010
Why?
Ascites
1
1981
56
0.010
Why?
Surveys and Questionnaires
1
2008
2607
0.010
Why?
Incidence
1
2004
1591
0.010
Why?
Tomography, X-Ray Computed
1
2009
2649
0.010
Why?
Levoleucovorin
1
1998
3
0.010
Why?
Pleural Neoplasms
1
1981
197
0.010
Why?
Femoral Nerve
1
1998
8
0.010
Why?
Peripheral Nervous System Neoplasms
1
1998
19
0.010
Why?
Acute Kidney Injury
1
1982
310
0.010
Why?
Fatal Outcome
1
1998
295
0.010
Why?
Child, Preschool
1
2004
3695
0.010
Why?
Administration, Oral
1
1999
682
0.010
Why?
Tetrahydrofolates
1
1996
13
0.010
Why?
Gallium Radioisotopes
1
1995
31
0.010
Why?
Animals
1
2015
27272
0.010
Why?
Patient Selection
1
1999
681
0.010
Why?
Antigens, Neoplasm
1
1995
332
0.010
Why?
Blood Cell Count
1
1993
79
0.010
Why?
Child
1
2004
7113
0.010
Why?
Iron
1
1993
165
0.010
Why?
Cyclophosphamide
2
1983
299
0.010
Why?
Drug Evaluation
1
1992
138
0.010
Why?
Blood Transfusion
1
1993
166
0.010
Why?
Bone Marrow
1
1993
445
0.010
Why?
Probability
2
1982
353
0.010
Why?
Doxorubicin
2
1983
298
0.010
Why?
Infusions, Intravenous
1
1990
434
0.010
Why?
Pyrimidines
1
1992
372
0.010
Why?
Tamoxifen
1
1983
168
0.000
Why?
Carcinoembryonic Antigen
1
1981
40
0.000
Why?
Menopause
1
1982
76
0.000
Why?
Magnesium
1
1982
178
0.000
Why?
Axilla
1
1982
104
0.000
Why?
Amino Acids
1
1982
245
0.000
Why?
Lymph Node Excision
1
1983
220
0.000
Why?
Pleural Effusion
1
1981
47
0.000
Why?
Radiotherapy
1
1983
331
0.000
Why?
Mastectomy
1
1983
245
0.000
Why?
Mitomycins
1
1979
13
0.000
Why?
Fever
1
1981
126
0.000
Why?
Remission, Spontaneous
1
1979
53
0.000
Why?
Calcium
1
1982
1171
0.000
Why?
Kozloff's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (291)
Explore
_
Co-Authors (35)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_